Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374696 | 0.98 | FOLH1 (0.61) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| SCHEMBL8768476 | 0.95 | FOLH1 (0.59) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| Succinic Acid SCHEMBL6229447 | 0.90 | FOLH1 (0.53) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| Terephthalic Acid SCHEMBL27748404 | 0.90 | TSHR (0.68) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| Toluene SCHEMBL27935612 | 0.88 | FOLH1 (0.52) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| SCHEMBL821015 | 0.86 | FOLH1 (0.50) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| SCHEMBL8104744 | 0.82 | FOLH1 (0.59) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| 4-Methylbenzoic Acid SCHEMBL7897437 | 0.82 | TSHR (0.58) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| SCHEMBL30365583 | 0.81 | FOLH1 (0.76) | FOLH1ALDH1A1ALOX15HPGDGAA | |
| SCHEMBL9668760 | 0.81 | GAA (0.55) | FOLH1ALDH1A1ALOX15HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104945500-B | Mixing agonist based on GIP is for treating metabolic disorder and obesity | 印第安纳大学研究及科技有限公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-102123723-B | Glucagon/GLP-1 receptor co-agonists | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2016-05-25 | — | — | CN | disclosed |
| CN-104945500-A | GIP-based mixed agonists for treatment of metabolic disorders and obesity | UNIV INDIANA RES & TECH CORP | 2015-09-30 | — | — | CN | disclosed |
| CN-102105159-B | GIP-based mixed agonists for the treatment of metabolic disorders and obesity | UNIV INDIANA RES & TECH CORP | 2015-07-08 | — | — | CN | disclosed |
| CN-103641907-A | Glucagon/glp-1 receptor co-agonists | UNIV INDIANA RES & TECH CORP | 2014-03-19 | — | — | CN | disclosed |
| CN-102123723-A | Glucagon/GLP-1 receptor co-agonists | UNIV INDIANA RES & TECH CORP | 2011-07-13 | — | — | CN | disclosed |
| CN-102105159-A | GIP-based mixed agonists for the treatment of metabolic disorders and obesity | UNIV INDIANA RES & TECH CORP | 2011-06-22 | — | — | CN | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| CN-1021735-C | Process for producing carbapenem compound | ERBA FARMITALIA (IT) | 1993-08-04 | — | — | CN | disclosed |
| EP-0201206-B1 | PENEM DERIVATIVES | FARMITALIA CARLO ERBA S.r.l. (IT) | 1990-07-25 | — | — | EP | disclosed |
| US-4863914-A | BACTERICIDES, ANTIBIOTICS | FARMITALIA CARLO ERBA (IT) | 1989-09-05 | — | — | US | disclosed |
| CN-86102350-A | Process for the preparation of novel * compounds | ERBA FARMITALIA (IT) | 1986-12-31 | — | — | CN | disclosed |
| EP-0201206-A1 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | FOLH1 492/4885ALDH1A1 1039/4885ALOX15 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.